AVIR
Atea Pharmaceuticals Inc
1 day chart
About AVIR
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in developing its product candidate, bemnifosbuvir, for the treatment of coronavirus disease 2019 (COVID-19), and its variants. The Company is also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV). The bemnifosbuvir (AT-527) for COVID-19 addresses key limitations of current therapies and explores combination therapy for specific patient populations. Bemnifosbuvir is an investigational, orally administered, non-mutagenic, non-teratogenic, direct-acting antiviral agent. The Company's SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy but also explores the effect of combination therapy in a smaller sub-set of patients who receive an antiviral drug along with bemnifosbuvir.
Buy US stocks in Australia starting with AVIR. Open an account and start investing today!
$265.21M
-
0.00%
699.15K
$3.29
$3.10
$3.27
$7.01
$2.94
AVIR FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in AVIR
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.